In sti tute of Mo lec u lar Bi ol ogy abd Ge net ics, Na tional Acad emy of Sci ences of Ukraine 150 Ac a de mi cian Zabolotnogo str., Kyiv, Ukraine, 03680 In tro duc tion. Ep i the lial ovar ian can cer (EOC) is one of the lead ing causes of can cer-re lated death in women and the lead ing cause of gynecologic can cer death. The lack of spe cific mark ers for EOC makes it dif fi cult to achieve the clin i cal ob jec tive for early de tec tion and therapy. Thus, the iden ti fi ca tion and char ac ter iza tion of novel ovar ian can cer mark ers is cru cial for the development of novel di ag nos tic and immunotherapeutic ap proaches in gynecologic on col ogy and for understanding the molecular mechanisms of malignant growth.
In tro duc tion. Ep i the lial ovar ian can cer (EOC) is one of the lead ing causes of can cer-re lated death in women and the lead ing cause of gynecologic can cer death. The lack of spe cific mark ers for EOC makes it dif fi cult to achieve the clin i cal ob jec tive for early de tec tion and therapy. Thus, the iden ti fi ca tion and char ac ter iza tion of novel ovar ian can cer mark ers is cru cial for the development of novel di ag nos tic and immunotherapeutic ap proaches in gynecologic on col ogy and for understanding the molecular mechanisms of malignant growth.
The re cent find ings sug gest that the so dium-depend ent phos phate trans porter NaPi2b could be considered as a po ten tial pro spec tive marker of ovar ian cancer. Firstly, NaPi2b is overexpressed in ovar ian can cer in com par i son to nor mal tis sues and other types of cancer [1] . Sec ondly, NaPi2b was re cently iden ti fied as MX35 can cer an ti gen by two in de pend ent ap proaches: a) screen ing of ovar ian can cer cell line OVCAR3 cDNA ex pres sion li brary with monoclonal an ti body MX35; and b) af fin ity pu ri fi ca tion of MX35 an ti gen fol lowed by mass spec trom e try anal y sis [2] . MX35 MAb was gen er ated more than 20 years ago at Me morial Sloan-Kettering Can cer Cen ter by im mu niz ing mice with fresh ovar ian car ci noma cells and screen ing gen er ated hybridomas with a panel of ovar ian can cer cell lines [3] .
Fur ther stud ies showed that MX35 an ti gen is expressed at high level inapproximately 90 % of hu man ovar ian ep i the lial can cers, which cre ated the base for us ing hu man ized MX35 MAb in early phase clin i cal tri als [3, 4] . In nor mal tis sues, the ex pres sion of sodium-de pend ent phos phate trans porter 2b at the pro tein level is restricted to small intestine [5] , lung [6] , liver [7] , mammary and salivary glands [8, 9] .
The hu man so dium-de pend ent phos phate transporter NaPi2b is en coded by SLC34A2 gene which be -longs to type II fam ily of so dium-de pend ent phos phate trans port ers (SLC34 fam ily). It is in volved in reg u lating ho meo sta sis of in or ganic phos phate in hu man body by in tes ti nal Pi ab sorp tion, whereas ho mol o gous sodium-de pend ent phos phate cotransporter NaPi2a is crit i cal for re nal Pi re ab sorp tion [10] .
NaPi2b is a transmembrane pro tein with mo lec u lar weight in 76-110 kDa range de pend ing on the state of glycosylation [6-9, 11, 12] . It is pre dicted to be anchored to the plasma mem brane through at least 8 highly hy dro pho bic a-he li cal re gions [13] . It has been pre vi ously pro posed that NaPi2b pos sesses a large extracellular loop (188-360 aa), 8 transmembrane domains and the N-and C-therminal cy to plas mic tails. The larg est extracellular loop con tains sev eral po ten tial sites of glycosylation and a re gion rich in cysteine res idues, which might be in volved in disulfide bond for mation [2] .
We have re cently de scribed the pro duc tion of several monoclonal an ti bod ies di rected against NaPi2b extracellular loop (188-360 aa) and nar rowed down their epitopes be tween amino res i dues 311 and 340 [14] . These an ti bod ies might have a ther a peu tic value, since NaPi2b is a mem brane protein and is overexpressed in ovarian cancer.
The re cent stud ies pro vided the ev i dence that mutatiîns in SLC34A2 gene are as so ci ated with pulmonary alveolar microlithiasis (PAM) which is char ac ter ized by the de po si tion of cal cium phos phate micro liths in lungs [15] . To date, there are no data which could link mutations in SLC34A2 gene to malignant transformation.
In this study we de scribe two mu ta tions in NaPi2b gene that could be po ten tially as so ci ated with ovar ian can cer: T330V in a large extracellular loop and a 6 aa de le tion in the C-ter mi nal end of trans porter. These mu ta tions, as well as oth ers were iden ti fied by bioinformatic anal y sis of NaPi2b se quences in var i ous DNA data bases. Fur ther more, we have cre ated ex pression con structs of wild type and mu tant forms of NaPi2b suit able for mak ing sta ble cell lines. High level of ex pres sion of wild type and mu tant forms of NaPi2b in es tab lished HEK293 sta ble cell lines was con firmed by West ern-blot anal y sis. Gen er ated cell lines will be used to study the reg u la tion of NaPi2b un der var i ous ex per i men tal con di tions, such as mitogenic stim u lation, treat ment of cells with sig nal transduction inhibitors, exposure to cellular stresses etc.
Ma te rial and Meth ods. Bioinformatic approaches. GeneBank data bases were searched for po ten tial mutations in so dium-de pend ent cotransporter NaPi2b. CLUSTALW (1.82) pro gram (www.ebi.ac.uk/clus talw/) was used for mul ti ple se quence align ment of differ ent EST clones cor re spond ing to NaPi2b.
Clon ing of wild type NaPi2b into pcDNA3.1. The full length cDNA clone of hu man NaPi2b (NaPi2b_WT) was am pli fied from the orig i nal clone DKFZp6860655Q2 (re ceived from RZPD gene bank) with prim ers con tain ing clon ing sites and se quences for the EE-tag (Ta ble). The am pli fied cDNA frag ment was then li gated into mam ma lian ex pres sion vec tor pcDNA3.1+ (Invitrogen, USA) that al lows the ex pression of cloned cDNA in mam ma lian cells un der the con trol of the CMV pro moter. Gen er ated cDNA plasmids were con firmed by re stric tion anal y sis and DNA se quenc ing. Plasmid DNA used in sub se quent stud ies was pu ri fied by DNA pu ri fi ca tion kit (Promega, USA). 
Oligonucleotide primers used for cloning and site-directed mutagenesis
Site-di rected mu ta gen e sis. 20 ng of the pcDNA3.1/ NaPi2b plasmid was am pli fied with 2.5 U of Pfu DNA poly mer ase in the pres ence of over lap ping prim ers for mu ta gen e sis (9 pmol of each). The prim ers con tained a mu ta tion (ac 988 gt for T330V and del1768-1785 nt for del6aa, see Ta ble) in the mid dle of the se quence. PCR am pli fi ca tion was per formed in 50 ml with 18-22 ther mal cy cles (95 o C for 30 s, 55 o C for 1 min and 68 o C for 16 min). Am pli fied DNA was pre cip i tated, redissolved in 15 ml of wa ter and then the pa ren tal dam-meth yl ated DNA was di gested with 10 U of DpnI for 1 h at 37 o C. 100 ml of XL1-Blue ultracompetent cells were trans formed with 4 ml of the re ac tion mixture, grown for 45 min in SOC me dium and plated onto LB-ampicillin plates. Plasmid DNA was pu ri fied by DNA pu ri fi ca tion kit (Promega, USA). Gen er ated muta tions were ver i fied by se quenc ing anal y sis.
Pro duc tion of sta ble HEK293 cells. Ini tially, the pro duced DNA con structs were linearized with ScaI restric tion en zyme (Fermentas, Lith u a nia) ac cord ing to the man u fac turer's rec om men da tions. Transfection of HEK293 cells with FuGene (Roche, Swit zer land) was per formed in 6 cm plates when cell den sity reached 60-70 %. 5 mg of each plasmid DNA (pcDNA3.1/ NaPi2b-WT, pcDNA3.1/NaPi2b-T330V, pcDNA3.1/ NaPi2b-D6 aa or empty vec tor) was mixed with 500 ml of stan dard DMEM me dium. FuGene re agent (10 ml) was added to each sam ple and in cu bated at room temper a ture for 10 min be fore the ad di tion to cells. Af ter 24 h in cu ba tion, the me dium was re placed with complete DMEM me dium (10 % FBS, 1 mM Glutamine, pen i cil lin (50 U/ml)/strep to my cin (0,25 mg/ml) an ti biot ics). Af ter 48 h, the me dium was re placed with complete DMEM me dium con tain ing 1mg/ml G418 an ti biotic (Gibco, USA).
Transfected cells were cul tured in the pres ence of G418 for 7-10 days in or der to elim i nate nontransfected cells. The gen er ated sta ble cell lines were cultured in the pres ence of G418.
Cell lysis and West ern-blot anal y sis. Stably transfected HEK293 cells were lysed in buffer con taining 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 0,5 % NP-40, and a mix ture of Halt Pro te ase In hib i tor Cock tail (Pierce, USA). Pro tein con cen tration was mea sured by Brad ford as say (Pierce, USA), and equal amounts of pro teins (10 mg) were sep a rated in 8 % SDS-PAGE and blot ted to polyvinylidene difluoride (PVDF) mem brane (Millipore, USA). The mem brane was blocked with 3 % BSA in PBS (phosphate-sa line buffer) con tain ing 0,1 % Tween-20 (PBST) for 1 h. Anti-NaPi2b and anti-EE-tag antibod ies were in cu bated with mem branes at 4 °C overnight. Gen er a tion of monoclonal an ti bod ies against the extracellular loop of trans porter was pre vi ously described [5] . Af ter wash ing with PBST, HRP-con jugated goat anti-mouse lgG 1:5000 (Promega, USA) was added to the mem brane for 1 h at RT. West ern blots were de vel oped us ing the ECL sys tem (Amersham, Swe den) and then ex posed to Agfa X-ray film.
Re sults and Dis cus sion. We have re cently iden tified so dium-de pend ent phos phate cotransporter NaPi2b as MX35 an ti gen which is overexpressed in 90 % cases of hu man ep i the lial ovar ian can cer [2, 3] . In nor mal cells, NaPi2b me di ates the trans-ep i the lial efflux of in or ganic phos phate and so dium ions across the api cal mem brane of entherocytes in small in tes tine and plays an im por tant role in the main te nance of phosphate ho meo sta sis in hu man body [16] . NaPi2b is also ex pressed on the api cal sur face of ep i the lial cells in other or gans to pro vide an ap pro pri ate in or ganic phosphate level in al ve o lar surfactant [6] , bile [7] , sa liva [9] , and epididymal fluid [11] . No ta bly, NaPi2b is expressed at a very low level in nor mal ovary, in con trary to the high ex pres sion in ep i the lial ovar ian can cer [1, 5] . So far, the ra tio nale for high level ex pres sion of NaPi2b trans porter in ovar ian can cer is not clear. This might re flect the in creased de mand in can cer cells for in or ganic phos phate which is re quired for biosynthetic pro cesses and sig nal transduction. The func tion of phos phate trans porter is known to be reg u lated by diverse extracellular stim uli, in clud ing FGF 23, EGF, glucocorticoids, vi ta min D and estrogens [17] [18] [19] [20] [21] . There fore, de reg u la tion of sig nal ing path ways in duced by oncogenic trans for ma tion may lead to the aug menta tion of nu tri ents up take through the in creased ex pression of trans port ers at the level of tran scrip tion and trans la tion.
We have per formed de tailed bioinformatic anal y sis of po ten tial mu ta tions in SLC34A2 gene in avail able da ta bases and com posed the map of se quence vari ations in hu man NaPi2b se quence (data not shown). This study al lowed us to iden tify 15 dif fer ences in the cod ing se quence of hu man NaPi2b: seven of them were found in genomic DNA of the pa tients suf fer ing from pul mo nary al ve o lar microlithiasis; one in genomic DNA of a pa tient with testicular microlithiasis; three in cDNA clones from ovar ian can cer cell lines and four from ap par ently nor mal tis sues.
Bioinformatic anal y sis of NaPi2b se quences from ovar ian can cer cell lines re vealed three mu ta tions poten tially as so ci ated with ovar ian can cer: a) sin gle amino acid sub sti tu tion T330V in a large extracellular loop; b) 6 aa de le tion (591-596 aa); and c) 56 aa de letion (461-519 aa) in C-ter mi nus of transporter (Fig. 1,  see inset) .
A point mu ta tion T330V is lo cated in a large extracellular loop of NaPi2b pro tein and there fore could in flu ence an ti genic prop er ties of trans porter. Corut et al. have de scribed T330M sub sti tu tion in NaPi2b and have in di cated that this mu ta tion might inac ti vate NaPi2b trans porter due to the sub sti tu tion of po lar res i due to non-po lar one [15] . So, this po si tion may rep re sent a hot spot of mu ta tion in NaPi2b, especially in ovarian cancer.
The iden ti fied de le tions in NaPi2b are lo cated in the C-ter mi nus tail -this re gion of the phos phate transporter is pos si bly re spon si ble for the in ter ac tion with bind ing part ners im pli cated in the reg u la tion of cel lu lar lo cal iza tion and func tion sim i larly to NaPi2a [22] . A 6 aa de le tion is flanked by short di rect re peats, which might be in volved in the mech a nism of mu ta gen e sis by rep li ca tion slip page [23] , site-spe cific re com bi na tion and oth ers. We pro pose that these mu ta tions may ex ist in ovar ian can cer and may influence NaPi2b cellular localization and function.
We have cre ated mu tant cDNA con structs of NaPi2b with a point mu ta tion T330V and a 6aa de le tion of 591 … 596 aa by site-di rected mu ta gen e sis. Un fortu nately, we were not suc cess ful in mak ing a 59 aa dele tion mu tant in mam ma lian ex pres sion plasmid. Cloning of wild type NaPi2b in frame with the N-ter mi nally lo cated EE-tag epitope into pcDNA3.1 vec tor was performed as de scribed in Ma te ri als and Meth ods. All generated con structs were linearized and used for sta ble transfection of HEK293 cells. Af ter 7-10 days se lection of transfected cells on geneticin con tain ing medium we have se lected col o nies for test ing NaPi2b expres sion.
The ex pres sion of NaPi2b (wild type and mu tant forms) in HEK293 was con firmed by West ern-blot anal y sis of to tal cell lysates with anti-EE monoclonal an ti body (Fig. 2, A) or anti-NaPi2b monoclonal an tibod ies (Fig. 2, B) . Fur ther more, we found that anti-NaPi2b MAb gen er ated against the extracellular loop of trans porter L2 (20/3) spe cif i cally re cog nises wild type and a 6 aa de le tion mu tant, but does not de tect the NaPi2b mu tant car ry ing sub sti tu tion T330V in the extracellular loop of NaPi2b lo cated within a re gion of epitope for L2 (20/3) MAb (311-340 aa). These data clearly in di cate that T330V sub sti tu tion of hy dro philic to nonpolar amino acid could be cru cial for the epitope rec og ni tion by L2 (20/3) MAb. It should be no ticed that the MX35 epitope is also lo cated in the same re gion of the large extracellular loop [2] and MX35 MAb does 98 GRYSHKOVA V. S. ET AL. not de tect NaPi2b mu tant car ry ing sub sti tu tion T330V as well (data not shown).
Con clu sions. We have cre ated sta ble cell lines express ing wild-type and mu tant forms of NaPi2b phosphate trans porter and have shown that T330V mu ta tion in the extracellular loop is not rec og nized by anti-NaPi2b L2 (20/3) MAb by West ern-blot anal y sis that could be ex plained by the de struc tion of the epitope for these an ti bod ies.
The gen er ated sta ble cell lines will be used for the fur ther anal y sis of phos phate trans porter NaPi2b in nor mal and trans formed cells. We are plan ning to inves ti gate the im pact of gen er ated mu ta tions on the phos phate trans port func tion and cel lu lar pro cesses, such as DNA biosynthesis, growth and proliferation.
The gen er ated sta ble cell lines will be avail able for re search ers elu ci dat ing the func tion of NaPi2b transporter and those who are study ing the in or ganic phosphate ho meo sta sis un der nor mal and patho log i cal conditions. Acknowledgements. This study was supported in part by grant from the National Academy (2); pcDNA3.1/NaPi2b-T330V (3) and pcDNA3.1 (4) 
